AAPL   329.90 (+2.35%)
MSFT   186.48 (+1.95%)
FB   230.99 (+2.08%)
GOOGL   1,443.17 (+2.04%)
AMZN   2,480.92 (+0.83%)
NVDA   358.12 (+2.13%)
CGC   16.77 (+0.84%)
BABA   219.59 (+0.71%)
MU   54.41 (+6.23%)
AMD   53.25 (+1.18%)
T   32.87 (+3.37%)
ACB   13.97 (-1.83%)
F   7.37 (+12.19%)
GILD   77.32 (-0.28%)
DIS   126.27 (+2.09%)
NFLX   417.65 (+0.80%)
BAC   28.35 (+5.86%)
BA   211.93 (+14.99%)
AAPL   329.90 (+2.35%)
MSFT   186.48 (+1.95%)
FB   230.99 (+2.08%)
GOOGL   1,443.17 (+2.04%)
AMZN   2,480.92 (+0.83%)
NVDA   358.12 (+2.13%)
CGC   16.77 (+0.84%)
BABA   219.59 (+0.71%)
MU   54.41 (+6.23%)
AMD   53.25 (+1.18%)
T   32.87 (+3.37%)
ACB   13.97 (-1.83%)
F   7.37 (+12.19%)
GILD   77.32 (-0.28%)
DIS   126.27 (+2.09%)
NFLX   417.65 (+0.80%)
BAC   28.35 (+5.86%)
BA   211.93 (+14.99%)
AAPL   329.90 (+2.35%)
MSFT   186.48 (+1.95%)
FB   230.99 (+2.08%)
GOOGL   1,443.17 (+2.04%)
AMZN   2,480.92 (+0.83%)
NVDA   358.12 (+2.13%)
CGC   16.77 (+0.84%)
BABA   219.59 (+0.71%)
MU   54.41 (+6.23%)
AMD   53.25 (+1.18%)
T   32.87 (+3.37%)
ACB   13.97 (-1.83%)
F   7.37 (+12.19%)
GILD   77.32 (-0.28%)
DIS   126.27 (+2.09%)
NFLX   417.65 (+0.80%)
BAC   28.35 (+5.86%)
BA   211.93 (+14.99%)
AAPL   329.90 (+2.35%)
MSFT   186.48 (+1.95%)
FB   230.99 (+2.08%)
GOOGL   1,443.17 (+2.04%)
AMZN   2,480.92 (+0.83%)
NVDA   358.12 (+2.13%)
CGC   16.77 (+0.84%)
BABA   219.59 (+0.71%)
MU   54.41 (+6.23%)
AMD   53.25 (+1.18%)
T   32.87 (+3.37%)
ACB   13.97 (-1.83%)
F   7.37 (+12.19%)
GILD   77.32 (-0.28%)
DIS   126.27 (+2.09%)
NFLX   417.65 (+0.80%)
BAC   28.35 (+5.86%)
BA   211.93 (+14.99%)
Log in

Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 Forty SevenAmarinReata PharmaceuticalsUnited TherapeuticsHorizon Therapeutics
SymbolNASDAQ:FTSVNASDAQ:AMRNNASDAQ:RETANASDAQ:UTHRNASDAQ:HZNP
Price Information
Current Price$95.51$6.90$129.91$124.11$47.75
52 Week RangeHoldBuyBuyBuyBuy
Beat the Market™ Rank
Overall Score1.21.81.61.31.9
Analysis Score1.24.34.41.32.5
Community Score2.63.12.62.23.3
Dividend Score0.00.00.00.00.0
Ownership Score2.01.01.01.01.0
Earnings & Valuation Score0.00.60.01.92.5
Analyst Ratings
Consensus RecommendationHoldBuyBuyBuyBuy
Consensus Price Target$65.95$17.23$257.38$127.88$46.92
% Upside from Price Target-30.95% downside149.90% upside98.12% upside3.03% upside-1.75% downside
Trade Information
Market Cap$4.60 billion$2.61 billion$4.50 billion$5.39 billion$9.18 billion
Beta0.42.712.030.871.2
Average Volume1,606,8367,337,448262,335631,9932,439,316
Sales & Book Value
Annual Revenue$15.68 million$429.76 million$26.52 million$1.45 billion$1.30 billion
Price / Sales293.336.18162.833.777.01
CashflowN/AN/AN/AN/A$3.39 per share
Price / CashN/AN/AN/AN/A14.07
Book Value$7.52 per share$1.63 per share$7.74 per share$63.36 per share$11.67 per share
Price / Book12.704.2316.781.964.09
Profitability
Net Income$-87,620,000.00$-22,650,000.00$-290,170,000.00$-104,500,000.00$573.02 million
EPS($2.34)($0.07)($9.54)($2.39)$1.94
Trailing P/E RatioN/AN/AN/A10.3516.87
Forward P/E RatioN/A13.79N/A11.4717.18
P/E GrowthN/AN/AN/AN/A$1.71
Net MarginsN/A-3.67%-1,542.06%36.59%43.06%
Return on Equity (ROE)-50.38%-4.05%-322.36%19.19%22.52%
Return on Assets (ROA)-44.35%-2.45%-65.04%13.33%10.37%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/A0.68%0.27%0.62%
Current Ratio14.81%2.63%3.25%8.91%2.39%
Quick Ratio14.81%2.34%3.25%8.46%2.27%
Ownership Information
Institutional Ownership Percentage71.77%44.36%67.33%98.11%90.08%
Insider Ownership Percentage37.40%2.75%31.70%10.90%4.30%
Miscellaneous
Employees57N/A1238601,200
Shares Outstanding48.16 million385.49 million33.24 million44.01 million190.78 million
Next Earnings DateN/A7/29/2020 (Estimated)8/13/2020 (Estimated)7/29/2020 (Estimated)8/5/2020 (Estimated)
OptionableNot OptionableOptionableOptionableOptionableOptionable

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.